Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitokiren in mild-moderate essential hypertension
NCT05359068Phase 3Completed
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Jun 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sitokiren in essential hypertension, sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Started Jun 2021; status: completed.
02
Drugs
sitokiren
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT05359068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05359068.